Top of this page
Skip navigation, go straight to the content

Clinical Studies Clinical studies index Zilucoplan (RA101495)

Zilucoplan (RA101495)

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Lay summary Publication (if available)
Paroxysmal Nocturnal Hemoglobinuria Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study Phase 2 RA101495-01.202
Ongoing
Paroxysmal Nocturnal Hemoglobinuria Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Phase 2 RA101495-01.201
Completed
LINK
Paroxysmal Nocturnal Hemoglobinuria Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Phase 2 RA101495-01.203
Completed

Generalized Myasthenia Gravis Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Phase 2 RA101495-02.201
Ongoing

Howard J.F., JAMA neurology 2020; 77(5):582–92
Immune-Mediated Necrotizing Myopathy Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy Phase 2 RA101495-02.202
Ongoing

Generalized Myasthenia Gravis Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE) Phase 3 RA101495-02.301
Ongoing
Generalized Myasthenia Gravis Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT) Phase 3  RA101495-02.302
Ongoing